🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07027267
Active, not recruiting Not applicable

Safety and Effectiveness of TurbAlign™ for Middle Turbinate Medialization After Functional Endoscopic Sinus Surgery

NCT07027267 · tracked via the Priya Life Science USA tracker
Sponsor
Spirair, Inc
Phase
Not applicable
Started
2025-08-04
Last updated
2026-04-27

Condition(s) studied

Sinus Endoscopic SurgeryTurbinate

Investigational drug(s) / intervention(s)

Implantation of Spirair device into the middle turbinatesTurbAlign

Implantation of Spirair device into the middle turbinates: The Spirair implant is designed to separate the middle turbinate from the lateral nasal wall during the healing phase associated with nasal/sinus surgery.

TurbAlign: The Spirair implant is designed to separate the middle turbinate from the lateral nasal wall during the healing phase associated with nasal/sinus surgery

Study summary

A study of a bioabsorbable implant to separate the middle turbinate from the lateral nasal wall associated with nasal/sinus surgery

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * ≥18 to ≤ 75 years of age at time of consent * Subject scheduled to undergo bilateral endoscopic sinus surgery * Willing and able to provide informed consent and comply with the study protocol Exclusion Criteria: * History of removal of one or both middle turbinates * Presence of significant concha bullosa, which requires surgical excision * Presence of non-viable tissue at the implantation site * Active infection at the implantation site * Chronic nasal decongestant use (i.e. Afrin, etc) * Recreational intra-nasal drug use within 12 months of enrollment * Documented evidence of a history (e.g., liver testing) of drug/alcohol abuse within 12 months of enrollment * Hypersensitivity to any investigational device materials including known or suspected allergy to poly(dioxanone) (PDO) or other bioabsorbable materials

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Northwest Community Hospital Arlington Heights Illinois
Rush University Medical Center Chicago Illinois
Tandem Clinical Research Marrero Louisiana
LSU Health Science Center Shreveport Louisiana
Houston Methodist ENT Specialists Houston Texas

More Spirair, Inc trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07027267 on ClinicalTrials.gov ↗ ← All trials in the USA